Fresenius completes mAbxience deal. Fresenius stock gains 1.37 percent.

Published on 10/07/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The transaction covers up to EUR 750 million in cash. Fresenius stock costs EUR 44.26 on October 7, 2026 after EUR 43.66, plus 1.37 percent.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius SE & Co. KGaA (ISIN DE000FRE5EN2) completed the acquisition of the remaining 45 percent of mAbxience for total consideration of up to EUR 750.00 million on September 30, 2026. The company announced the transaction on October 1, 2026, in an Fresenius release. Fresenius stock was trading at EUR 44.26 at Lang & Schwarz on October 7, 2026, up 1.37 percent versus the prior close of EUR 43.66.

Full ownership expands biosimilars control

The deal gives Fresenius full ownership of the biosimilars platform after it had held a 55 percent stake since 2022. The consideration includes a contingent payment of EUR 50.00 million tied to site approvals, while Fresenius said no new financing was required.

mAbxience operates three production facilities in Spain and Latin America and employs more than 1,300 people. Its portfolio includes four products on the market and eight candidates in development, giving Fresenius control over research, manufacturing and commercialization.

Second-quarter growth adds operating support

The latest reported quarter also provides a measurable operating backdrop. According to Fresenius Investor Relations, second-quarter 2026 revenue increased 6.00 percent year over year to EUR 5.864 billion, while EBIT rose 10.00 percent to EUR 719.00 million.

Core net income climbed 14.00 percent to EUR 470.00 million in the second quarter of 2026, and core earnings per share increased 14.00 percent to EUR 0.83. The combination of higher revenue and faster profit growth makes margin and cash conversion important measures for the next update.

Stock trades above the prior close

Fresenius shares trade on Xetra under ticker FRE and belong to the DAX 40. The primary listing had a 52-week range of EUR 35.11 to EUR 52.96, while market capitalization stood at EUR 24.9 billion on October 7, 2026.

The next Fresenius results event is scheduled for November 4, 2026, when the company plans to discuss third-quarter 2026 results, according to its investor-relations calendar. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.